Abivax

Abivax company information, Employees & Contact Information

Explore related pages

Related company profiles:

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.

Company Details

Employees
89
Founded
-
Address
7-11, Boulevard Haussmann, Paris,île-De-France 75009,france
Phone
+33(0)1 53 83 08 41
Email
in****@****vax.com
Industry
Biotechnology
Website
abivax.com
HQ
Paris, Île-de-France
Looking for a particular Abivax employee's phone or email?

Abivax Questions

News

Abivax's obefazimod Shows 34% Clinical Response in UC at 8 Weeks | ABVX Stock News - Stock Titan

Abivax's obefazimod Shows 34% Clinical Response in UC at 8 Weeks | ABVX Stock News Stock Titan

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data - TradingView

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data TradingView

Oklahoma City News - The Oklahoman - FinancialContent

Oklahoma City News - The Oklahoman FinancialContent

Abivax Suspends European Trading to Launch Major US Stock Offering: Key Details Inside - Stock Titan

Abivax Suspends European Trading to Launch Major US Stock Offering: Key Details Inside Stock Titan

Abivax announces trading resumption of its ordinary shares on Euronext Paris - TradingView

Abivax announces trading resumption of its ordinary shares on Euronext Paris TradingView

EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares - boerse.de - boerse.de

EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares - boerse.de boerse.de

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO) - Yahoo Finance

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO) Yahoo Finance

$747.5M Fundraise: Biotech Abivax Strengthens Position After Phase 3 UC Drug Success and Widening Losses - Stock Titan

$747.5M Fundraise: Biotech Abivax Strengthens Position After Phase 3 UC Drug Success and Widening Losses Stock Titan

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris - TradingView

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris TradingView

Major Index Milestone: Biotech Abivax Secures Spots in Both CAC Mid 60 and SBF 120 Indices - Stock Titan

Major Index Milestone: Biotech Abivax Secures Spots in Both CAC Mid 60 and SBF 120 Indices Stock Titan

Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market - Yahoo Finance

Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market Yahoo Finance

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) - TradingView

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) TradingView

Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market - Yahoo Finance

Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market Yahoo Finance

Abivax Announces Launch of Public Offering - TradingView

Abivax Announces Launch of Public Offering TradingView

Abivax Trading Resumes Following Major US Public Offering Launch: What Investors Should Know - Stock Titan

Abivax Trading Resumes Following Major US Public Offering Launch: What Investors Should Know Stock Titan

Abivax Highlights Obefazimod Ulcerative Colitis Program With New Data to be Presented at the UEG Week 2023 - Yahoo Finance

Abivax Highlights Obefazimod Ulcerative Colitis Program With New Data to be Presented at the UEG Week 2023 Yahoo Finance

Key Phase 3 Results: Abivax's Novel Oral UC Drug Obefazimod Shows Significant Efficacy in Major Trials - Stock Titan

Key Phase 3 Results: Abivax's Novel Oral UC Drug Obefazimod Shows Significant Efficacy in Major Trials Stock Titan

Abivax Secures Up to EUR 150M from Two Structured Debt Financing Transactions - Yahoo Finance

Abivax Secures Up to EUR 150M from Two Structured Debt Financing Transactions Yahoo Finance

Abivax Phase 3 Trial Results Coming: Why Executives Just Bought 120,000 Shares Ahead of Q3 Readout - Stock Titan

Abivax Phase 3 Trial Results Coming: Why Executives Just Bought 120,000 Shares Ahead of Q3 Readout Stock Titan

Abivax Appoints Patrick Malloy as Senior Vice President Investor Relations - Yahoo Finance

Abivax Appoints Patrick Malloy as Senior Vice President Investor Relations Yahoo Finance

Abivax Releases the Results of its June 5, 2023 Ordinary and Extraordinary General Meeting - Yahoo Finance

Abivax Releases the Results of its June 5, 2023 Ordinary and Extraordinary General Meeting Yahoo Finance

Abivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price Range - Yahoo Finance

Abivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price Range Yahoo Finance

Abivax Announces Plans to Conduct Registered Public Offering in the United States - Yahoo Finance

Abivax Announces Plans to Conduct Registered Public Offering in the United States Yahoo Finance

Landmark Ulcerative Colitis Trial Hits Major Milestone: 1,275 Patients Enrolled for New Treatment - Stock Titan

Landmark Ulcerative Colitis Trial Hits Major Milestone: 1,275 Patients Enrolled for New Treatment Stock Titan

Abivax presents first-half 2023 financial results - Yahoo Finance

Abivax presents first-half 2023 financial results Yahoo Finance

Abivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors - Yahoo Finance

Abivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors Yahoo Finance

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies - Sahm

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies Sahm

Abivax Announces a Change in Its Governance - Yahoo Finance

Abivax Announces a Change in Its Governance Yahoo Finance

ABIVAX: Addressing the need for long-term effective treatments for inflammatory bowel diseases - Open Access Government

ABIVAX: Addressing the need for long-term effective treatments for inflammatory bowel diseases Open Access Government

ABVX Stock Price and Chart — NASDAQ:ABVX - TradingView

ABVX Stock Price and Chart — NASDAQ:ABVX TradingView

Changing the treatment paradigm in Inflammatory Bowel Diseases - Open Access Government

Changing the treatment paradigm in Inflammatory Bowel Diseases Open Access Government

EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis - sharewise.com

EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis sharewise.com

EQS-News: Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerati - boerse.de - boerse.de

EQS-News: Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerati - boerse.de boerse.de

EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting - boerse.de - boerse.de

EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting - boerse.de boerse.de

EQS-News: Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - boerse.de - boerse.de

EQS-News: Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - boerse.de boerse.de

Phase 2 Study: First Ever Evidence of Treatment-Induced Reduction in HIV Reservoirs - drugdiscoverytrends.com

Phase 2 Study: First Ever Evidence of Treatment-Induced Reduction in HIV Reservoirs drugdiscoverytrends.com

Top Abivax Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant